
Greenwich LifeSciences, Inc. (GLSI) Market Cap
Greenwich LifeSciences, Inc. has a market capitalization of $327.9M.
Financials based on reported quarter end 2025-09-30
Price: $23.67
โผ -1.27 (-5.09%)
Market Cap: 327.94M
NASDAQ ยท time unavailable
CEO: Snehal S. Patel
Sector: Healthcare
Industry: Biotechnology
IPO Date: 2020-09-25
Website: https://greenwichlifesciences.com
Greenwich LifeSciences, Inc. (GLSI) - Company Information
Market Cap: 327.94M ยท Sector: Healthcare
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. Greenwich LifeSciences, Inc. was incorporated in 2006 and is headquartered in Stafford, Texas.
Analyst Sentiment
Based on 2 ratings
Analyst 1Y Forecast: $50.00
Average target (based on 1 sources)
Consensus Price Target
Low
$50
Median
$50
High
$50
Average
$50
Potential Upside: 111.2%
Price & Moving Averages
Related Companies in Healthcare

CROSS COUNTRY HEALTHCARE INC (CCRN)
Healthcare
$0.33B
Mkt Cap

CLEARPOINT NEURO INC (CLPT)
Healthcare
$0.33B
Mkt Cap

EDITAS MEDICINE INC (EDIT)
Healthcare
$0.33B
Mkt Cap

SIGA TECHNOLOGIES INC (SIGA)
Healthcare
$0.32B
Mkt Cap

ANAVEX LIFE SCIENCES CORP (AVXL)
Healthcare
$0.33B
Mkt Cap

ABEONA THERAPEUTICS INC (ABEO)
Healthcare
$0.32B
Mkt Cap
Fundamentals Overview
๐ AI Financial Analysis
Powered by StockMarketInfo"GLSI reported minimal revenue of $0 for the quarter ended September 30, 2025, reflecting a challenging operating environment, with a net loss of approximately $4.15M. The company does not generate free cash flow, indicating potential liquidity issues. Total assets stand at $3.81M, with total liabilities of $1.62M, resulting in total equity of $2.18M. Its financial stability is somewhat bolstered by a net debt position of -$3.81M, suggesting it has a cash surplus over liabilities. Despite a lack of revenue, the stock price increased by over 128% over the past year, signaling strong market sentiment and potential speculative interest. However, without revenue generation or positive cash flow, long-term sustainability remains in question. Continued monitoring of operational performance and financial health will be critical for potential investors."
Revenue Growth
No revenue generated, indicating a pre-revenue status.
Profitability
Significant net loss of $4.15M reflects poor profitability.
Cash Flow Quality
Negative operational cash flow indicates liquidity challenges.
Leverage & Balance Sheet
Strong equity position with cash surplus over liabilities.
Shareholder Returns
Strong price appreciation of 128.27% over the past year.
Analyst Sentiment & Valuation
Current price substantially above target consensus, suggesting speculative valuation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.